Characteristics of patients with and without post-treatment Lyme disease syndrome (PTLDS)
| Risk factor | Group; no. (%) of patients | Crude odds ratio (95% CI) | |
|---|---|---|---|
| With PTLDS n = 27 | No PTLDS n = 240 | ||
| Age, yr | |||
| < 18 | 2 (7) | 37 (15) | 1.0 (ref.) |
| 18–64 | 21 (78) | 145 (60) | 2.7 (0.6–11.9) |
| ≥ 65 | 4 (15) | 58 (24) | 1.3 (0.2–7.5) |
| Sex | |||
| Female | 8 (30) | 94 (39) | 1.0 (ref.) |
| Male | 19 (70) | 146 (61) | 0.7 (0.3–1.6) |
| Symptoms upon presentation | |||
| Arthralgia | 16 (59) | 70 (29) | 3.5 (1.6–7.9) |
| Headache | 19 (70) | 126 (52) | 2.2 (0.9–5.1) |
| Myalgias | 13 (48) | 100 (42) | 1.3 (0.6–2.9) |
| Fatigue | 19 (70) | 138 (58) | 1.8 (0.7–4.2) |
| Insomnia | 5 (19) | 30 (12) | 1.6 (0.6–4.5)* |
| Tremor | 4 (15) | 5 (2) | 8.2 (2.1–32.6)* |
| Paresthesias | 7 (26) | 32 (13) | 2.3 (0.9–5.8)* |
| Difficulty concentrating | 4 (15) | 8 (3) | 5.1 (1.4–18.1)* |
| Clinical stage | |||
| Early localized | 6 (22) | 84 (35) | 1.0 (ref.) |
| Early disseminated | 15 (56) | 121 (50) | 1.7 (0.7–7.9) |
| Late disseminated | 6 (22) | 35 (15) | 2.4 (0.6–4.7) |
| Study period | |||
| 2004–2013 | 3 (11) | 62 (26) | 1.0 (ref.) |
| 2014–2015 | 4 (15) | 69 (29) | 1.2 (0.3–5.6) |
| 2016–2017 | 20 (74) | 109 (45) | 3.8 (1.1–13.4)* |
Note: CI = confidence interval, ref. = reference category.
↵* Fisher exact test.